# Safety and Efficacy Study of a New Chemotherapy Agent to Treat Metastatic Breast Cancer

> **NCT00288249** · PHASE2 · COMPLETED · sponsor: **Bayer** · enrollment: 82 (actual)

## Conditions studied

- Breast Neoplasms
- Breast Cancer, Metastatic

## Interventions

- **DRUG:** Sagopilone (BAY86-5302, ZK 219477)
- **DRUG:** Sagopilone (BAY86-5302, ZK 219477)
- **DRUG:** Sagopilone (BAY86-5302, ZK 219477)
- **DRUG:** Sagopilone (BAY86-5302, ZK 219477)

## Key facts

- **NCT ID:** NCT00288249
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-12
- **Primary completion:** 2008-03
- **Final completion:** 2009-01
- **Target enrollment:** 82 (ACTUAL)
- **Last updated:** 2014-12-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00288249

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00288249, "Safety and Efficacy Study of a New Chemotherapy Agent to Treat Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00288249. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*